DAWN (Day One Biopharmaceuticals) Interest Expense : $0.0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Day One Biopharmaceuticals's interest expense for the three months ended in Sep. 2024 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Day One Biopharmaceuticals's Operating Income for the three months ended in Sep. 2024 was $ 29.6 Mil. Day One Biopharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $ 0.0 Mil. GuruFocus does not calculate Day One Biopharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Day One Biopharmaceuticals Interest Expense Historical Data

The historical data trend for Day One Biopharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Day One Biopharmaceuticals Interest Expense Chart

Day One Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-2.08

-0.03

Day One Biopharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Day One Biopharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Day One Biopharmaceuticals (NAS:DAWN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Day One Biopharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $0.0 Mil. Its Operating Income for the three months ended in Sep. 2024 was $29.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $2.5 Mil.

Day One Biopharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

GuruFocus does not calculate Day One Biopharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Day One Biopharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Day One Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005

Website

https://www.dayonebio.com

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Executives

York Charles N Ii	officer: COO, CFO and Secretary	901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Samuel C. Blackman	officer: Chief Medical Officer	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Jeremy Bender	director, officer: Chief Executive Officer	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Ai Day 1 Llc	10 percent owner	40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant	director	2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p.	10 percent owner	2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone	director	395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc.	10 percent owner	ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc.	10 percent owner	9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080